Close

Leerink Swann Lifts Target on Amarin (AMRN) After FDA Approval

July 27, 2012 7:29 AM EDT
Get Alerts AMRN Hot Sheet
Price: $0.84 -2.33%

Rating Summary:
    6 Buy, 12 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 2 | New: 35
Join SI Premium – FREE
Leerink Swann boosted its price target on Outperform-rated Amarin Corporation (NASDAQ: AMRN) from $25 to $27 after AMR101 (Vascepa) was approved with a robust label.

"Vascepa label looks mostly as expected in our view, with full MARINE data including LDL neutrality/ApoB reduction shown and approval of 4g dose... NCE exclusivity status would be a positive, but not essential now that at least two patents will be listed in the Orange Book from day-one," the firm notes.

They also said AMRN in a solid position ahead of a potential company sale, temporary commercial partnership, or in house launch in early 2013.

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $15.32 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change